Skip to Main content Skip to Navigation
New interface
Journal articles

Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma

Marianne Delville 1, 2, 3, * Fabien Touzot 1, 3 Chloé Couzin 1, 3 Isabelle Hmitou 1, 3 Lounes Djerroudi 1, 3 Amani Ouedrani 1, 3 François Lefrère 3, 1 Caroline Tuchman-Durand 1, 3 Chloe Mollet 1, 3 Jean-Roch Fabreguettes 4, 5 Nicolas Ferry 6 Laurent Laganier 1, 3 Alessandra Magnani 3, 1 Elisa Magrin 3, 1 Valerie Jolaine 7 Asier Sáez-Cirión 8 Orit Wolstein 9 Geoffrey Symonds 9 Pierre Frange 10, 11 Hélène Moins-Teisserenc 12, 13 Marie-Laure Chaix-Baudier 14 Antoine Toubert 13, 12 Jérome Larghero 15 Nathalie Parquet 16 Anne Brignier 16 Françoise Barré-Sinoussi 17 Eric Oksenhendler 16 Marina Cavazzana 3, 2, 1 
Abstract : Although the risk of developing lymphoma has decreased in the highly active antiretroviral therapy era, this cancer remains the major cause of mortality in HIV-infected patients. Autologous hematopoietic stem cell transplantation (ASCT) outcome does not differ for HIV-infected versus HIV-uninfected patients. We propose to develop a new treatment for HIV-associated high-risk lymphoma based on autologous transplantation of two genetically modified products: CD4+ T lymphocytes and CD34+ hematopoietic stem cells (HSPCs). The cells will be transduced ex vivo with the Cal-1 lentiviral vector encoding for both a short hairpin RNA (shRNA) against CCR5 (sh5) and the HIV-1 fusion inhibitor C46. The transduced cells will be resistant to HIV infection by two complementary mechanisms: impaired binding of the virus to the cellular CCR5 co-receptor and decreased fusion of the virus as C46 interacts with gp41 and inhibits HIV infection. This phase I/II pilot study, also entitled GENHIV, will involve two French participating centers: Saint Louis Hospital and Necker Hospital in Paris. We plan to enroll five HIV-1-infected patients presenting with high-risk lymphoma and require a treatment with ASCT. The primary objective of this study is to evaluate the safety, feasibility, and success of engraftment of Cal-1 gene-transduced CD4+ T lymphocytes and CD34+ HSPCs.
Document type :
Journal articles
Complete list of metadata

Cited literature [20 references]  Display  Hide  Download
Contributor : Asier Saez-Cirion Connect in order to contact the contributor
Submitted on : Tuesday, April 21, 2020 - 7:05:34 PM
Last modification on : Thursday, October 20, 2022 - 3:10:07 PM


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



Marianne Delville, Fabien Touzot, Chloé Couzin, Isabelle Hmitou, Lounes Djerroudi, et al.. Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma. Molecular Therapy - Methods and Clinical Development, 2019, 13, pp.303-309. ⟨10.1016/j.omtm.2019.02.006⟩. ⟨pasteur-02549969⟩



Record views


Files downloads